While those familiar with the field of phlebology understand that foam sclerotherapy can be utilized for treatment of venous reflux like that which occurs in the great saphenous vein, the small saphenous vein, perforating veins and the Giacomini vein, the majority of physicians equate sclerotherapy with cosmetic treatment of medically insignificant, unsightly telangiectasias.
Proposals for treatment of significant varicose vein disease with sclerotherapy (even foam sclerotherapy) fall on deaf ears when submitted to an insurance board where reviewers universally define limiting situations in which vessels must be less than 6 mm or involve non-saphenous reflux. The dye has been cast in their opinion. The word sclerotherapy equals cosmetic therapy and serves as a red flag for disallowing re-imbursement. This is not at all a contrivance to avoid authorized insurance coverage by these reviewers. They just do not understand and certainly do not know about the use of foam sclerotherapy for treatment of major venous reflux.
Why don't they understand? Because we haven't told them. We haven't spoken with a united voice. We need to be direct and certain in our declaration that foam sclerotherapy really works for large venous reflux. We should not say that it may be effective or that it is an adjunctive therapy but instead say that it really works on a consistent basis.
A new alarm has to be sounded. We have to alert insurance companies and physicians in general that a totally new and effective procedure utilizing foam sclerotherapy can and does adequately treat severe large vessel reflux like that which occurs in the great saphenous vein and the small saphenous vein.
The answer lies in an official designation and a new name for the aggressive treatment of large vessel reflux with foam sclerotherapy. I propose that the new name be 'endovenous chemical ablation'.
All phlebologists who deal with serious venous disease should take a stand regarding the efficacy of endovenous chemical ablation (foam sclerotherapy) for treatment of large refluxing veins such as the great and small saphenous vein. The plain and simple fact is that this new, improved form of treatment has entered the arena for eradication of large vessel reflux, which causes medically significant varicose vein disease. This new form of treatment is efficient, economical and may be reapplied after partial failure without inconvenience or expense.
Until we all rename foam sclerotherapy as endovenous chemical ablation and proclaim its efficiency and effectiveness, patients will miss the advantages it provides and insurance review boards will continue to refuse coverage because they equate the term sclerotherapy with cosmetic therapy. 
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